This site is intended for healthcare professionals only
LoginRegister
USFDAUS FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
CDSCO Clears Abbotts phase IV Trial Of Dydrogesterone MR TabletCDSCO Clears Abbott's phase IV Trial Of Dydrogesterone MR Tablet
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorderUCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Full Inspection of Packaged Water Units in Maharashtra Mandatory, Says FSSAIFull Inspection of Packaged Water Units in Maharashtra Mandatory, Says FSSAI
Pharma Firms To Face Periodic Inspection As HC Flags Effluent RisksPharma Firms To Face Periodic Inspection As HC Flags Effluent Risks
AstraZeneca expands Global Hub in Bangalore with Rs 166 crore investmentAstraZeneca expands Global Hub in Bangalore with Rs 166 crore investment
Merck Enflonsia wins ACIP backing for RSV protection in infants under 8 monthsMerck Enflonsia wins ACIP backing for RSV protection in infants under 8 months
Intas Gets SEC Nod to Import, Market Anti-Cancer Drug Serplulimab, Phase IV Trial MandatedIntas Gets SEC Nod to Import, Market Anti-Cancer Drug Serplulimab, Phase IV Trial Mandated
label updates for Bristol Myers Squibb 2 CAR T cell therapiesUSFDA approves label updates for Bristol Myers Squibb 2 CAR T cell therapies
Bayer Eylea 8 mgBayer Eylea 8 mg with extended 6-month treatment interval approved in EU for retinal diseases
Abbott Gets SEC Nod to Market Chlordiazepoxide Tablets for Anxiety, Alcohol WithdrawalAbbott Gets SEC Nod to Market Chlordiazepoxide Tablets for Anxiety, Alcohol Withdrawal
Pfizer Gets CDSCO Panel Nod to Conduct Phase IIIb Trial of Rimegepant for Menstrual MigrainePfizer Gets CDSCO Panel Nod to Conduct Phase IIIb Trial of Rimegepant for Menstrual Migraine
X